Table 4 Median treatment duration, median TTP, and median PFS of everolimus by duration of previous VEGF-targeted treatment (efficacy population)

<3 (n = 54) vs. ≥3 (n = 203)

6.6 (3–10)

7.9 (4–11)

7.1 (4–11)

7.1 (5–9)

7.5 (6–10)

7.4 (6–9)

p = .87

p = .62

<6 (n = 105) vs. ≥6 (n = 152)

6.6 (4–9)

6.8 (4–10)

6.6 (4–10)

7.5 (5–11)

8.1 (7–10)

7.8 (5–10)

p = .86

p = .70

<9 (n = 133) vs. ≥9 (n = 124)

6.6 (4–9)

6.8 (4–10)

6.6 (4–10)

7.5 (5–11)

8.2 (7–11)

8.1 (7–10)

p = .79

p = .74